Foreign Language Math Science Social Science Business Engineering & Technology Arts & Humanities History Miscellaneous Standardized tests
  1. Science
  2. Health Science
  3. Oncology
BeyondSpring Pharmaceuticals to Present Plinabulin
BeyondSpring Pharmaceuticals to Present Plinabulin
Beyond trastuzumab – the potential roles for lapatinib
Beyond trastuzumab – the potential roles for lapatinib
Beyond the `Breast Cancer" Gene (BRCA): Why Food Is Your Medicine
Beyond the `Breast Cancer" Gene (BRCA): Why Food Is Your Medicine
Beyond Genes, Proteins, and Abstracts: A Framework to Capture Scientific Claims
Beyond Genes, Proteins, and Abstracts: A Framework to Capture Scientific Claims
Beyond Being An Ally: Balancing Professionalism & Activism February 7, 2015
Beyond Being An Ally: Balancing Professionalism & Activism February 7, 2015
Bevacizumab promotes venous thromboembolism through the induction of
Bevacizumab promotes venous thromboembolism through the induction of
BEV8_v1.2_Bevacizumab_3rdlineLGGliomaChildren
BEV8_v1.2_Bevacizumab_3rdlineLGGliomaChildren
Betting on Nanotech Therapies Brian Gormley WSJ.Sep 12, 2007
Betting on Nanotech Therapies Brian Gormley WSJ.Sep 12, 2007
better tools for commissioning and early diagnosis
better tools for commissioning and early diagnosis
Better Cancer Care, an Action Plan
Better Cancer Care, an Action Plan
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc Please share
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc Please share
Complete deletion of Apc results in severe polyposis in mice Please share
Complete deletion of Apc results in severe polyposis in mice Please share
Complementary genomic approaches highlight the osteosarcoma
Complementary genomic approaches highlight the osteosarcoma
Complementary and Integrative Medicine
Complementary and Integrative Medicine
Complement C3f serum levels may predict breast cancer risk in
Complement C3f serum levels may predict breast cancer risk in
Competitors: Johnson and Johnson`s Simponi and Stelara, UCB`s
Competitors: Johnson and Johnson`s Simponi and Stelara, UCB`s
Competing views on cancer C S A
Competing views on cancer C S A
Competing Risks: Modelling Cause Specific Hazard and Crude
Competing Risks: Modelling Cause Specific Hazard and Crude
Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis
Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis
Competing Causes of Death and Medical Comorbidities
Competing Causes of Death and Medical Comorbidities
Competency Assessment Tool for Therapeutic Communication 2009
Competency Assessment Tool for Therapeutic Communication 2009
Compassionate Drug Use
Compassionate Drug Use
Compass Rose
Compass Rose
Comparisons between different polychemotherapy regimens
Comparisons between different polychemotherapy regimens